Lindsey Shapiro, PhD,  science writer—

Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in people with platinum-resistant ovarian cancer.

When added to standard care, Imunon’s immunotherapy candidate IMNN-001 extended the average survival for people with newly diagnosed advanced ovarian cancer by more than…

The U.S. Food and Drug Administration (FDA) has given Verastem Oncology the green light to start clinical testing of its oral treatment candidate VS-7375…

Tepylute (thiotepa), a chemotherapy medication from Shorla Oncology that was approved last year for treating certain breast and ovarian cancers, has launched in the…

Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…

Blood levels of the MUC5AC protein could help predict outcomes in people who have surgery for pancreatic ductal adenocarcinoma (PDA), the most common type of…

April 21 marks AML World Awareness Day — a global effort to boost recognition of acute myeloid leukemia (AML) and raise funds for research…

The LY6H and GRM3 proteins could serve as potential biomarkers of glioma-related epilepsy (GRE), according to a study. Among people with gliomas, both proteins…

Adding the investigational therapy LAM561 to standard of care treatment may delay disease progression or death in people with newly diagnosed glioblastoma whose tumors exhibit…

Tumors in children with aggressive gliomas that formed in the spinal cord all exhibited genetic changes that might be able to be targeted therapeutically,…